Proteomics will yield precise therapeutic target

Before beginning any discussion of advanced prostate cancer, it is importantto point out that early detection of the disease has dramatically reducedthe cohort of men who present with locally advanced or metastatic disease.A review of the Eastern Virginia Medical School database indicates that,of the 320 new diagnoses of prostate cancer in 2003, only 5% presented withstage T3 disease, and 7% presented with stage M+ disease.